| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development expense | - | 1,439,564 | ||
| General and administrative expenses | - | 4,576,524 | ||
| Operating expenses | - | 6,016,088 | ||
| Loss from operations | - | -6,016,088 | ||
| Finance income | - | 40,004 | ||
| Represents the amount if change in fair value of debentures | - | -200,000 | ||
| Total other income | - | -159,996 | ||
| Foreign exchange gain/loss | 10,828 | - | ||
| Net income (loss), including portion attributable to noncontrolling interest | - | -6,176,084 | ||
| Comprehensive income (loss), net of tax, attributable to parent | -2 | - | ||
| Earnings per share, basic | -1.12 | -0.43 | ||
| Earnings per share, diluted | -1.12 | -0.43 | ||
| Weighted average number of shares outstanding, basic | 18,631,668 | 14,284,261 | ||
| Weighted average number of shares outstanding, diluted | 18,631,668 | 14,284,261 | ||
Medicus Pharma Ltd. (MDCX)
Medicus Pharma Ltd. (MDCX)